Transdermal Buprenorphine Use for Pain Management in Palliative Care

Abstract

Cancer related pain is prevalent among patients with a cancer diagnosis, occurring from the tumor itself or as a result of treatment. Many patients require opioid therapy to manage pain and providers must balance efficacy with side effects. Transdermal buprenorphine (TDB) has shown promise for pain management, however, the maximum dose available in the US is considered low, resulting in doubts of efficacy. This study set out to assess if the patch strengths available in the US (5–20 mcg/hour) are able to provide analgesia for patients with cancer in a palliative medicine clinic. This retrospective chart review analyzed patient charts for outpatient TDB use within a palliative medicine clinic in the United States. Patients had to have a follow up visit with the clinic in order to be included. Sixty-eight patients were included for analysis with 54 (79%) continuing at least 28 days and 37 (54%) continuing for at least 84 days. The median change in pain score was 0, though 25 (46%) of patients reported a decrease of 1 or more points at the first follow up. TDB is a viable option for cancer related pain for select patients, demonstrated by duration of use and stable reporting of pain.

Keywords:

• Buprenorphine
• palliative care
• pain management
• cancer
• transdermal opioid

Authorship confirmation statement

All listed authors contributed to the contents of this research in a meaningful manner. All authors attest to its contents and are satisfied with the final manuscript.

Author disclosure statement

There is no conflict of interests or disclosures to report for all authors. There was no funding for this research.